首页 | 本学科首页   官方微博 | 高级检索  
     


Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design,synthesis, and X-ray cocrystal structure
Authors:Canan Koch Stacie S  Thoresen Lars H  Tikhe Jayashree G  Maegley Karen A  Almassy Robert J  Li Jianke  Yu Xiao-Hong  Zook Scott E  Kumpf Robert A  Zhang Cathy  Boritzki Theodore J  Mansour Rena N  Zhang Kanyin E  Ekker Anne  Calabrese Chris R  Curtin Nicola J  Kyle Suzanne  Thomas Huw D  Wang Lan-Zhen  Calvert A Hilary  Golding Bernard T  Griffin Roger J  Newell David R  Webber Stephen E  Hostomsky Zdenek
Affiliation:Pfizer Global Research and Development, La Jolla/Agouron Pharmaceuticals, Inc., 10770 Science Center Drive, San Diego, California 92121, USA. stacie.canan@pfizer.com
Abstract:
A series of novel compounds have been designed that are potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1), and the activity and physical properties have been characterized. The new structural classes, 3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-ones and 3,4-dihydropyrrolo[4,3,2-de]isoquinolin-5-(1H)-ones, have conformationally locked benzamide cores that specifically interact with the PARP-1 protein. The compounds have been evaluated with in vitro cellular assays that measure the ability of the PARP-1 inhibitors to enhance the effect of cytotoxic agents against cancer cell lines.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号